Arcutis Biotherapeutics Says FDA Approved SNDA For ZORYVE (Roflumilast) Cream, 0.15%, For Treatment Of Mild To Moderate Atopic Dermatitis In Adult And Pediatric Patients 6 Years Of Age And Older
Arcutis Biotherapeutics Says FDA Approved SNDA For ZORYVE (Roflumilast) Cream, 0.15%, For Treatment Of Mild To Moderate Atopic Dermatitis In Adult And Pediatric Patients 6 Years Of Age And Older
arcutis biotherapeutics表示FDA已批准SNDA用於0.15%的ZORYVE(Roflumilast)乳膏，用於治療6歲及以上的成人和兒童患者的輕至中度特應性皮炎
ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been specifically developed to be a treatment option for long-term disease control.
ZORYVE是一種每日一次的無甾體藥膏，可快速清除疾病，顯著減輕瘙癢，並專門開發成爲長期疾病控制的治療選擇。
Arcutis intends to make ZORYVE cream 0.15% widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of July.
Arcutis計劃通過主要批發商和皮膚科藥房渠道使ZORYVE cream 0.15%成爲一種新的治療選擇，到七月底時將廣泛推廣。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。